Literature DB >> 22733972

Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells.

B P Huderson1, T T Duplessis, C C Williams, H C Seger, C G Marsden, K J Pouey, S M Hill, B G Rowan.   

Abstract

Elevated phosphorylation of estrogen receptor α (ERα) at serines 118 (S118) and 167 (S167) is associated with favorable outcome for tamoxifen adjuvant therapy and may serve as surrogate markers for a functional ERα signaling pathway in breast cancer. It is possible that loss of phosphorylation at S118 and/or S167 could disrupt ERα signaling, resulting in aggressive ERα-independent breast cancer cells. To this end, MCF-7 breast cancer cells were stably transfected with an ERα-specific short hairpin RNA that reduced endogenous ERα. The resulting cell line was stably transfected with wild-type ERα (ER-AB cells), or ERα containing serine to alanine mutation at S118 or S167 (S118A cells and S167A cells, respectively). These stable cell lines expressed approximately equivalent ERα compared with parental MCF-7 cells and were evaluated for growth, morphology, migration/invasion, and ERα-regulated gene expression. S118A cells and S167A cells exhibited increased growth and migration/invasion in vitro. Forward- and side-scatter flow cytometry revealed that S167A cells were smaller in size, and both S118A and S167A cells exhibited less cellular complexity. S118A and S167A cells expressed pancytokeratin and membrane localization of β-catenin and did not express vimentin, indicating retention of epithelial lineage markers. Expression of ERα-target genes and other genes regulated by ERα signaling or involved in breast cancer were markedly altered in both S118A and S167A cells. In summary, attenuated phosphorylation of ERα at S118 and S167 significantly affected cellular physiology and behavior in MCF-7 breast cancer cells, resulting in increased growth, migration/invasion, compromised expression of ERα target genes, and markedly altered gene expression patterns.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733972      PMCID: PMC3423624          DOI: 10.1210/en.2011-2001

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  39 in total

Review 1.  Steroid receptor phosphorylation: a key modulator of multiple receptor functions.

Authors:  Nancy L Weigel; Nicole L Moore
Journal:  Mol Endocrinol       Date:  2007-05-29

2.  Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

Authors:  J S Foster; D C Henley; A Bukovsky; P Seth; J Wimalasena
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 3.  Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Endocr Relat Cancer       Date:  2011-07-04       Impact factor: 5.678

Review 4.  Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Authors:  C Kent Osborne; Jiang Shou; Suleiman Massarweh; Rachel Schiff
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167.

Authors:  P B Joel; J Smith; T W Sturgill; T L Fisher; J Blenis; D A Lannigan
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

6.  Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo.

Authors:  Leigh Murphy; Tracy Cherlet; Adewale Adeyinka; Yulian Niu; Linda Snell; Peter Watson
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

7.  Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.

Authors:  Mathieu Dalvai; Kerstin Bystricky
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

Review 8.  Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer.

Authors:  Eric R Fearon
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

9.  Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients.

Authors:  Jie Jiang; Naveed Sarwar; David Peston; Elena Kulinskaya; Sami Shousha; R Charles Coombes; Simak Ali
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

10.  Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha.

Authors:  Mariam H Al-Dhaheri; Brian G Rowan
Journal:  Nucl Recept Signal       Date:  2006-04-28
View more
  10 in total

1.  The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.

Authors:  Berry Button; Sarah Croessmann; David Chu; D Marc Rosen; Daniel J Zabransky; W Brian Dalton; Karen Cravero; Kelly Kyker-Snowman; Ian Waters; Swathi Karthikeyan; Eric S Christenson; Josh Donaldson; Tasha Hunter; Lauren Dennison; Cody Ramin; Betty May; Richard Roden; Dana Petry; Deborah K Armstrong; Kala Visvanathan; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2018-12-17       Impact factor: 4.872

2.  The Phosphorylated Estrogen Receptor α (ER) Cistrome Identifies a Subset of Active Enhancers Enriched for Direct ER-DNA Binding and the Transcription Factor GRHL2.

Authors:  Kyle T Helzer; Mary Szatkowski Ozers; Mark B Meyer; Nancy A Benkusky; Natalia Solodin; Rebecca M Reese; Christopher L Warren; J Wesley Pike; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2019-01-16       Impact factor: 4.272

3.  Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.

Authors:  Kathleen A O'Leary; Fatou Jallow; Debra E Rugowski; Ruth Sullivan; Kerstin W Sinkevicius; Geoffrey L Greene; Linda A Schuler
Journal:  Endocrinology       Date:  2013-09-24       Impact factor: 4.736

Review 4.  Structure and function of the co-chaperone protein phosphatase 5 in cancer.

Authors:  Rebecca A Sager; Natela Dushukyan; Mark Woodford; Mehdi Mollapour
Journal:  Cell Stress Chaperones       Date:  2020-04-02       Impact factor: 3.667

Review 5.  The complex nature of oestrogen signalling in breast cancer: enemy or ally?

Authors:  Yulia Lipovka; John P Konhilas
Journal:  Biosci Rep       Date:  2016-06-30       Impact factor: 3.840

6.  Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.

Authors:  Josefine Bostner; Anya Alayev; Adi Y Berman; Tommy Fornander; Bo Nordenskjöld; Marina K Holz; Olle Stål
Journal:  Breast Cancer Res Treat       Date:  2017-11-11       Impact factor: 4.872

7.  A Ternary Mixture of Common Chemicals Perturbs Benign Human Breast Epithelial Cells More Than the Same Chemicals Do Individually.

Authors:  Shanaz H Dairkee; Gloria Luciani-Torres; Dan H Moore; Ian M Jaffee; William H Goodson
Journal:  Toxicol Sci       Date:  2018-09-01       Impact factor: 4.849

8.  SYK allelic loss and the role of Syk-regulated genes in breast cancer survival.

Authors:  Jan Blancato; Ashley Graves; Banafsheh Rashidi; Maria Moroni; Leopold Tchobe; Metin Ozdemirli; Bhaskar Kallakury; Kepher H Makambi; Catalin Marian; Susette C Mueller
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

9.  Cellular inhibitor of apoptosis protein 2 promotes the epithelial-mesenchymal transition in triple-negative breast cancer cells through activation of the AKT signaling pathway.

Authors:  Su Ji Jo; Pil-Gu Park; Hye-Ran Cha; Sung Gwe Ahn; Min Jung Kim; Hyemi Kim; Ja Seung Koo; Joon Jeong; Jeon Han Park; Seung Myung Dong; Jae Myun Lee
Journal:  Oncotarget       Date:  2017-08-12

Review 10.  Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.

Authors:  Sarah A Jeffreys; Branka Powter; Bavanthi Balakrishnar; Kelly Mok; Patsy Soon; André Franken; Hans Neubauer; Paul de Souza; Therese M Becker
Journal:  Cells       Date:  2020-09-11       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.